Physician profile
Richard W Hell
NPI 1114937927
$3,934.70
in general payments reported to CMS, 2019-2025
34 companies · $796 in 2025
The $796 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $912 · 2020: $350 · 2021: $500 · 2022: $506 · 2023: $322 · 2024: $549 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,636 · Education: $31.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,635.55 |
| Education | $31.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,581.61 | 2019-2025 | |
| Janssen Biotech, INC. | $305.36 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $298.06 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $180.27 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $163.63 | 2019-2022 | |
| Redhill Biopharma INC. | $136.00 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2020 | |
| Merck Sharp & Dohme LLC | $107.84 | 2019-2023 | Dificid |
| Ironwood Pharmaceuticals, INC | $84.57 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $82.00 | 2019-2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $81.90 | 2020-2024 | |
| Celgene Corporation | $81.10 | 2021-2023 | Zeposia |
| Daiichi Sankyo INC. | $65.10 | 2019-2022 | |
| Qol Medical, LLC | $58.57 | 2019-2023 | Sucraid |
| Ipsen Biopharmaceuticals, INC | $55.00 | 2024-2025 | Iqirvo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $45.86 | 2022-2025 | Dupixent |
| Celltrion USA INC. | $45.17 | 2024-2025 | Zymfentra, Vegzelma |
| Phathom Pharmaceuticals, INC. | $44.49 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $38.59 | 2019-2021 | |
| Allergan, INC. | $36.97 | 2019-2020 | |
| Ardelyx, INC. | $35.76 | 2023-2025 | Ibsrela |
| Romark Laboratories, Lc | $31.66 | 2019 | |
| Madrigal Pharmaceuticals | $30.25 | 2025 | Rezdiffra |
| Endo Pharmaceuticals INC. | $28.30 | 2019 | |
| Lilly USA, LLC | $26.04 | 2025 | Omvoh |
| Biocon Biologics INC | $23.72 | 2025 | Yesintek |
| Alfasigma USA, INC. | $23.30 | 2020 | |
| Olympus America INC. | $22.07 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.74 | 2023 | Cyltezo |
| Exact Sciences Corporation | $17.36 | 2023 | |
| Pfizer INC. | $16.64 | 2019 | |
| Vivus LLC | $14.63 | 2021 | |
| Medtronic, INC. | $13.11 | 2024 | Gi Genius |
| Alnylam Pharmaceuticals INC. | $13.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Hell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.